Skin Disorders News

Gusacitinib produced significant and rapid improvement of severity and pain in patients with moderate to severe chronic hand eczema, according to a study presented at AAD VMX 2021.

In this video, Michael J. Cork, BSC, MB, PhD, FRCP, discusses how data from posters being presented at AAD VMX 2021 on dupilumab reinforce his experience of how life-changing dupilumab treatment can be in children with atopic dermatitis.

Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.

Long-term use of tralokinumab is safe and efficacious in the treatment of atopic dermatitis, according to a presentation at AAD VMX 2021.

Experimental studies indicate that sleep loss can lead to elevated concentrations of proinflammatory cytokines and enhance the perception of pain among patients with immune-mediated inflammatory diseases, according to a speaker here.

Abrocitinib combined with a medicated topical therapy was effective, well tolerated and improved quality of life in adolescents with atopic dermatitis, according to phase 3 results from the JADE TEEN Study.

Patients with skin allergies who wear certain types of face masks may experience adverse events, according to a presenter at this year’s virtual American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

By the time Lilly Stairs was diagnosed with psoriatic arthritis at the age of 19 — following an arduous series of tests and doctor visits — she had already been living with an autoimmune disease for 12 years.

The FDA approved Dupixent for use with other medicines to treat patients with chronic rhinosinusitis with nasal polyps, the agency, Regeneron Pharmaceuticals and Sanofi all announced today.

Numerous studies have implicated Staphylococcus aureus in the development of eczema.